News | November 14, 2022
Aurobindo Pharma Q2 FY23 revenue down 3.4%
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
The Group will continue to make proactive investments of its management resources in the life science business
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
The acquisition is for an enterprise value of Rs. 218 crores
Subscribe To Our Newsletter & Stay Updated
